No Data
Sanxin Healthcare: Report for the first quarter of 2025
Jiangxi Sanxin Medtec (300453.SZ): Net income for the first quarter is 53.7257 million yuan, a year-on-year increase of 0.20%.
Gelonghui reported on April 27 that Jiangxi Sanxin Medtec (300453.SZ) published its Q1 2025 report, with revenue of 0.361 billion yuan, a year-on-year increase of 8.88%; net income attributable to shareholders of the listed company was 53.7257 million yuan, an increase of 0.20% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 50.5037 million yuan, representing a year-on-year increase of 7.93%; EPS was 0.1028 yuan.
Jiangxi Sanxin Medtec (300453.SZ): Recently, the company's PTA high-pressure balloon dilation catheter has been selected for the centralized procurement project of medical consumables, including the peripheral vascular interventional guide pathways in 27
On April 3, according to Gelonghui, Jiangxi Sanxin Medtec (300453.SZ) recently stated in an investor relations activity that the company is deeply focusing on vascular access research and vascular interventional product development centered around arteriovenous fistula protection. New product registration certificates have been obtained for PTA high-pressure balloon dilatation catheters. As a product with vast potential to replace imports, the launch of this product is expected to further accelerate the pace of domestic substitution and benefit a wide range of hemodialysis patients. Recently, the PTA high-pressure balloon dilatation catheter has been selected for four types of medical consumable centralized procurement projects in 27 provincial alliances for peripheral vascular interventional guiding paths, which is expected to quickly achieve "price for quantity" through centralized procurement.
Jiangxi Sanxin Medtec (300453.SZ): In terms of overseas business, the company focuses on expanding into Emerging Markets such as Southeast Asia, South America, and Africa.
Gelonghui reported on April 3 that Jiangxi Sanxin Medtec (300453.SZ) recently expressed in investor relations activities that in terms of overseas Business, the company focuses on expanding into Emerging Markets such as Southeast Asia, South America, and Africa. By broadening the scope of overseas self-held certificates and accelerating market access, while taking into account various factors such as the policies and environments of different countries and regions, the company is pushing forward its Global Strategy.
Sanxin Healthcare: 2024 Annual Report
Sanxin Healthcare: 2024 Annual Report Summary
Jiangxi Sanxin Medtec Co.,Ltd. (SZSE:300453) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
